• Profile
Close

Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with HCV genotype 2, 4, 5, or 6 infection without cirrhosis

Clinical Gastroenterology and Hepatology Oct 04, 2017

Asselah T, et al. - This study was performed to investigate the efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus (HCV) genotype 2, 4, 5, or 6 infection without cirrhosis in 3 separate phase 3 trials. With virologic failure in less than 1%, eight weeks’ treatment with glecaprevir/pibrentasivr produced an sustained virologic response at 12 weeks after treatment (SVR12) in at least 93% of patients with chronic HCV genotype 2, 4, 5, or 6 infection without cirrhosis in 3 Phase 3 studies. The drug combination had a safety profile comparable to 12 week’s treatment with glecaprevir/pibrentasvir.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay